Dados B3 › WEGE3 × VAMO3 · Português
Each row uses the most recent year in which BOTH companies have the figure, and says which year that is. A cell with ! carries a caveat — hover to read it. We do not name a winner: that would be a recommendation, and this site does not give any.
| indicator | WEGE3 | VAMO3 | year |
|---|---|---|---|
| ROE | 32.2% | 0.0% | 2025 |
| ROIC | 38.5% | 13.8% | 2025 |
| ROA | 16.1% | 1.5% | 2025 |
| Gross margin | 33.5% | 52.4% | 2025 |
| EBIT margin | 19.6% | 45.4% | 2025 |
| Net margin | 16.6% | 5.7% | 2025 |
| Net debt/EBITDA | -0.30x | 3.28x | 2025 |
| Current ratio | 1.55x | 1.81x | 2025 |
| Revenue growth (1y) | 7.4% | 22.5% | 2025 |
| Revenue growth (5y CAGR) | 18.5% | 30.6% | 2025 |
| Piotroski F-Score | 5/9 | 5/9 | 2025 |
Priced at the first session on or after the day each filing became public — never the period close.
| indicator | WEGE3 | VAMO3 | year |
|---|---|---|---|
| P/E | 33.09x | — | 2025 |
| P/B | 12.11x | 1.55x | 2025 |
| EV/EBITDA | 23.14x | 4.37x | 2025 |
| FCF yield | 1.8% | -23.1% | 2025 |
Numbers on this page are live. Data version 2026-09-01-supressao-declarada · page generated 2026-09-08 14:48 UTC. If this does not match /saude, you are reading a cached copy.
Home · Methodology · Transparency · Audit it